HCW Biologics Inc (HCWB)

[Frankestin]

Wong Hing C. (CEO and 10% owner): Purchased 92,500 shares at $26.00 each, for a total of $2,405,000.
Rebecca Byam (CFO): Purchased 8,462 shares at $26.00 each, for a total of $220,012.
Scott T. Garrett (Director): Purchased 5,385 shares at $26.00 each, for a total of $140,010.
Gary M. Winer (Director): Purchased 2,308 shares at $26.00 each, for a total of $60,008.
Rick S. Greene (Director): Purchased 962 shares at $26.00 each, for a total of $25,012.
Lee Flowers (SVP of Business Development): Purchased 962 shares at $26.00 each, for a total of $25,012.
Investors aren’t actually paying $26/share. They’re converting existing debt into equity at that “nominal” price — and getting compensated with warrants and shares of another company to make up the difference from the real value.
Wugen is a privately held company that has raised over $200 million in venture capital funding, backed by investors such as Aisling Capital .
Relationship with HCW Biologics
Wugen has acquired rights to certain molecules developed by HCW Biologics, generating revenue for HCW Biologics from the sale of licensed molecules.
Wugen Presents Positive Phase 2 Data for WU-CART-007